Table 3.
Parameter Estimates of the Logistic Regression Models for the Relationships Between Upadacitinib Plasma Cavg and the Probability of Achieving Different Efficacy End Points (NRI) in Week 16
| End Point | Parameter | Estimate (%RSE) | 95%CI |
|---|---|---|---|
| EASI‐75 | Intercept | −2.43 (23%) | −3.5 to −1.35 |
| Emax | 5.35 (17% a ) | 3.06 to 9.36 | |
| EC50 (ng/mL) | 18.6 (26% a ) | 4.28 to 81.1 | |
| EASI‐90 | Intercept | −3.87 (26%) | −5.85 to −1.9 |
| Emax | 6.2 (13% a ) | 3.86 to 9.95 | |
| EC50 (ng/mL) | 18.1 (29% a ) | 3.5 to 93.7 | |
| IGA 0/1 | Intercept | −4.03 (28%) | −6.21 to −1.84 |
| Emax | 5.78 (12% a ) | 3.78 to 8.83 | |
| EC50 (ng/mL) | 12.8 (31% a ) | 2.77 to 59.3 |
a
The parameter was estimated on a transformed exponential scale and the %RSE is given on this scale.